In patients suffering from an interleukin-1 (IL-1) driven inflammatory disease, continuation of IL-1 inhibition is important because inflammation in these diseases is not controlled by the standard immunosuppressive drugs used after renal transplantation, and when anti-IL-1 directed therapy is stopped these patients are at high risk of recurrence of inflammation, associated with severe symptoms, such as arthritis, peritonitis, meningitis and many others. The gene discussed is IL1B; the disease is Arthritis.